OC
AMPH icon

Optima Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Optima Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20
Closed -$536 – 208
2025
Q4 		$536 Buy
+20
New +$515 ﹤0.01% 1177

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Optima Capital's AMPH Position: Q1 2026 in Review

Optima Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 20 shares — an estimated $536 sold.

Optima Capital first reported a position in AMPH in Q4 2025 and held it in 1 quarter. The position peaked at $536 in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Optima Capital reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Optima Capital sold 20 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $536.
  • Optima Capital first reported a position in Amphastar Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Optima Capital's Amphastar Pharmaceuticals position peaked at $536 in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.